| 刘剑飞,李 枫,王凝芳,李 军,张 健,王 峰.肝动脉灌注化疗栓塞联合射频消融对中晚期肝癌患者生存率、肝功能和T淋巴细胞亚群的影响[J].,2021,(9):1669-1672 |
| 肝动脉灌注化疗栓塞联合射频消融对中晚期肝癌患者生存率、肝功能和T淋巴细胞亚群的影响 |
| Effect of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation on Survival Rate, Liver Function and T Lymphocyte Subsets in Patients with Middle and Advanced Stage Liver Cancer |
| 投稿时间：2020-08-23 修订日期：2020-09-18 |
| DOI：10.13241/j.cnki.pmb.2021.09.015 |
| 中文关键词: 肝动脉灌注化疗栓塞 射频消融 中晚期 肝癌 生存率 肝功能 T淋巴细胞亚群 |
| 英文关键词: Transcatheter arterial chemoembolization Radiofrequency ablation Middle and advanced stage Liver cancer Survival rate Liver function T lymphocyte subsets |
| 基金项目:辽宁省自然科学基金指导计划项目（20170540254） |
|
| 摘要点击次数: 987 |
| 全文下载次数: 688 |
| 中文摘要: |
| 摘要 目的：探讨肝动脉灌注化疗栓塞（TACE）联合射频消融（RFA）对中晚期肝癌患者生存率、肝功能和T淋巴细胞亚群的影响。方法：选取2014年7月~2018年4月期间我院收治的中晚期肝癌患者126例，根据随机数字表法将患者分为对照组和研究组，各63例。对照组给予TACE治疗，研究组则在对照组的基础上联合RFA治疗，比较两组患者疗效、生存率、肝功能、T淋巴细胞亚群及不良反应情况。结果：研究组治疗后临床总有效率为69.84%（44/63），显著高于对照组患者的50.79%（32/63）（P<0.05）。两组患者治疗后丙氨酸氨基转移酶（ALT）、总胆红素（TBIL）、天门冬氨酸氨基转移酶（AST）均较治疗前降低，且研究组低于对照组（P<0.05）。两组治疗后CD4+、CD4+/CD8+较治疗前降低，但研究组高于对照组（P<0.05）；CD8+较治疗前升高，但研究组低于对照组（P<0.05）。两组不良反应发生率比较差异无统计学意义（P>0.05）。研究组患者1年、2年生存率均高于对照组（P<0.05）。结论：TACE联合RFA治疗中晚期肝癌患者，安全性较好，疗效较好，可有效改善患者肝功能，减轻机体免疫抑制，提高患者生存率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) on the survival rate, liver function and T lymphocyte subsets of patients with middle and advanced stage liver cancer. Methods: From July 2014 to April 2018, 126 patients with middle and advanced stage liver cancer in our hospital were selected, they were randomly divided into control group and study group, 63 cases in each group. The control group was treated with TACE, while the study group was treated with RFA on the basis of the control group. The curative effect, survival rate, liver function, T lymphocyte subsets and adverse reactions of the two groups were compared. Results: The total clinical effective rate of the study group after treatment was 69.84% (44/63), which was significantly higher than 50.79% (32/63) of the control group (P<0.05). Alanine aminotransferase (ALT), total bilirubin (TBIL) and total bilirubin (AST) in the two groups after treatment were lower than those before treatment, and the study group was lower than control group (P<0.05). After treatment, CD4+, CD4+/ CD8+ of the two groups were lower than before treatment, but the study group was higher than the control group (P<0.05). CD8+ was higher that before treatment, but the study group was lower than control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). The 1-year and 2-year survival rates in the study group were higher than those in control group (P<0.05). Conclusion: TACE combined with RFA is safe and effective in the treatment of middle and advanced stage liver cancer. It can effectively improve the liver function, reduce the immunosuppression and improve the survival rate of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
